189 related articles for article (PubMed ID: 19893043)
1. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.
Xia SJ; Holder DD; Pawel BR; Zhang C; Barr FG
Am J Pathol; 2009 Dec; 175(6):2600-8. PubMed ID: 19893043
[TBL] [Abstract][Full Text] [Related]
2. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
3. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.
Naini S; Etheridge KT; Adam SJ; Qualman SJ; Bentley RC; Counter CM; Linardic CM
Cancer Res; 2008 Dec; 68(23):9583-8. PubMed ID: 19047133
[TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
Hu Q; Yuan Y; Wang C
PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
[TBL] [Abstract][Full Text] [Related]
6. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
Xia SJ; Rajput P; Strzelecki DM; Barr FG
Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
[TBL] [Abstract][Full Text] [Related]
7. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
[TBL] [Abstract][Full Text] [Related]
8. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
9. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.
Wang W; Slevin M; Kumar S; Kumar P
Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327
[TBL] [Abstract][Full Text] [Related]
10. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
[TBL] [Abstract][Full Text] [Related]
11. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.
Zhang Y; Wang C
Oncogene; 2011 Aug; 30(32):3549-62. PubMed ID: 21423212
[TBL] [Abstract][Full Text] [Related]
12. PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.
Charytonowicz E; Matushansky I; Doménech JD; Castillo-Martín M; Ladanyi M; Cordon-Cardo C; Ziman M
Clin Transl Oncol; 2012 Mar; 14(3):197-206. PubMed ID: 22374423
[TBL] [Abstract][Full Text] [Related]
13. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
14. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Cao L; Yu Y; Bilke S; Walker RL; Mayeenuddin LH; Azorsa DO; Yang F; Pineda M; Helman LJ; Meltzer PS
Cancer Res; 2010 Aug; 70(16):6497-508. PubMed ID: 20663909
[TBL] [Abstract][Full Text] [Related]
16. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.
Jothi M; Nishijo K; Keller C; Mal AK
Cell Cycle; 2012 Mar; 11(5):895-908. PubMed ID: 22333587
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
Xia SJ; Barr FG
Oncogene; 2004 Sep; 23(41):6864-71. PubMed ID: 15286710
[TBL] [Abstract][Full Text] [Related]
18. IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).
Picchione F; Pritchard C; Lagutina I; Janke L; Grosveld GC
Carcinogenesis; 2011 Apr; 32(4):452-61. PubMed ID: 21177767
[TBL] [Abstract][Full Text] [Related]
19. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
20. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]